BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim KRQ, Nguyen Q, Yokota T. DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy. Int J Mol Sci 2020;21:E729. [PMID: 31979100 DOI: 10.3390/ijms21030729] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Chen TH, Wu YZ, Tseng YH. Early-Onset Infantile Facioscapulohumeral Muscular Dystrophy: A Timely Review. Int J Mol Sci 2020;21:E7783. [PMID: 33096728 DOI: 10.3390/ijms21207783] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Potulska-Chromik A, Jędrzejowska M, Gos M, Rosiak E, Kierdaszuk B, Maruszak A, Opuchlik A, Zekanowski C, Fichna JP. Pathogenic Mutations and Putative Phenotype-Affecting Variants in Polish Myofibrillar Myopathy Patients. J Clin Med 2021;10:914. [PMID: 33652732 DOI: 10.3390/jcm10050914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nguyen TH, Conotte S, Belayew A, Declèves AE, Legrand A, Tassin A. Hypoxia and Hypoxia-Inducible Factor Signaling in Muscular Dystrophies: Cause and Consequences. Int J Mol Sci 2021;22:7220. [PMID: 34281273 DOI: 10.3390/ijms22137220] [Reference Citation Analysis]
4 Schätzl T, Kaiser L, Deigner HP. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update. Orphanet J Rare Dis 2021;16:129. [PMID: 33712050 DOI: 10.1186/s13023-021-01760-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bury M, Le Calvé B, Ferbeyre G, Blank V, Lessard F. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy. Trends Cell Biol 2021;31:331-44. [PMID: 33676803 DOI: 10.1016/j.tcb.2021.01.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chetta M, Tarsitano M, Vicari L, Saracino A, Bukvic N. In Silico Analysis of Possible Interaction between Host Genomic Transcription Factors (TFs) and Zika Virus (ZikaSPH2015) Strain with Combinatorial Gene Regulation; Virus Versus Host-The Game Reloaded. Pathogens 2021;10:69. [PMID: 33466592 DOI: 10.3390/pathogens10010069] [Reference Citation Analysis]
7 Lim KRQ, Bittel A, Maruyama R, Echigoya Y, Nguyen Q, Huang Y, Dzierlega K, Zhang A, Chen YW, Yokota T. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy. Mol Ther 2021;29:848-58. [PMID: 33068777 DOI: 10.1016/j.ymthe.2020.10.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
8 Le Gall L, Sidlauskaite E, Mariot V, Dumonceaux J. Therapeutic Strategies Targeting DUX4 in FSHD. J Clin Med 2020;9:E2886. [PMID: 32906621 DOI: 10.3390/jcm9092886] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Anselmo M, Coffman S, Larson M, Vera K, Lee E, McConville M, Kyba M, Keller-Ross ML. Baroreflex sensitivity in facioscapulohumeral muscular dystrophy. Physiol Rep 2022;10:e15277. [PMID: 35451178 DOI: 10.14814/phy2.15277] [Reference Citation Analysis]
10 Lim KRQ, Yokota T. Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy. Front Pharmacol 2021;12:642858. [PMID: 33776777 DOI: 10.3389/fphar.2021.642858] [Reference Citation Analysis]
11 Joubert R, Mariot V, Charpentier M, Concordet JP, Dumonceaux J. Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD? J Pers Med 2020;11:7. [PMID: 33374516 DOI: 10.3390/jpm11010007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sidlauskaite E, Le Gall L, Mariot V, Dumonceaux J. DUX4 Expression in FSHD Muscles: Focus on Its mRNA Regulation. J Pers Med 2020;10:E73. [PMID: 32731450 DOI: 10.3390/jpm10030073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Lu-Nguyen N, Malerba A, Herath S, Dickson G, Popplewell L. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model. Hum Mol Genet 2021;30:1398-412. [PMID: 33987655 DOI: 10.1093/hmg/ddab136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Li H, Huang H, Long W, Zuo J, Huang H. Herbal medicine significantly improved muscle function in a patient with type 1 facioscapulohumeral muscular dystrophy: A case report. Explore (NY) 2021;17:247-51. [PMID: 32505519 DOI: 10.1016/j.explore.2020.05.009] [Reference Citation Analysis]
15 Mocciaro E, Runfola V, Ghezzi P, Pannese M, Gabellini D. DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy. Cells 2021;10:3322. [PMID: 34943834 DOI: 10.3390/cells10123322] [Reference Citation Analysis]
16 Jagannathan S. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy. Biochim Biophys Acta Mol Basis Dis 2022;:166367. [PMID: 35158020 DOI: 10.1016/j.bbadis.2022.166367] [Reference Citation Analysis]